93 related articles for article (PubMed ID: 31174839)
1. DUX4 Pathological Expression: Causes and Consequences in Cancer.
Dib C; Zakharova V; Popova E; Kiseleva E; Chernyak B; Lipinski M; Vassetzky YS
Trends Cancer; 2019 May; 5(5):268-271. PubMed ID: 31174839
[TBL] [Abstract][Full Text] [Related]
2. Control of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Cancer.
Karpukhina A; Tiukacheva E; Dib C; Vassetzky YS
Trends Mol Med; 2021 Jun; 27(6):588-601. PubMed ID: 33863674
[TBL] [Abstract][Full Text] [Related]
3. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
4. Facioscapulohumeral muscular dystrophy.
Tawil R
Handb Clin Neurol; 2018; 148():541-548. PubMed ID: 29478599
[TBL] [Abstract][Full Text] [Related]
5. Facioscapulohumeral dystrophy myoblasts efficiently repair moderate levels of oxidative DNA damage.
Bou Saada Y; Dib C; Dmitriev P; Hamade A; Carnac G; Laoudj-Chenivesse D; Lipinski M; Vassetzky YS
Histochem Cell Biol; 2016 Apr; 145(4):475-83. PubMed ID: 26860865
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy.
Himeda CL; Jones TI; Jones PL
Mol Ther; 2016 Mar; 24(3):527-35. PubMed ID: 26527377
[TBL] [Abstract][Full Text] [Related]
7. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
Banerji CRS; Panamarova M; Hebaishi H; White RB; Relaix F; Severini S; Zammit PS
Nat Commun; 2017 Dec; 8(1):2152. PubMed ID: 29255294
[TBL] [Abstract][Full Text] [Related]
8. DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD.
Klingler C; Ashley J; Shi K; Stiefvater A; Kyba M; Sinnreich M; Aihara H; Kinter J
FASEB J; 2020 Mar; 34(3):4573-4590. PubMed ID: 32020675
[TBL] [Abstract][Full Text] [Related]
9. Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions.
Statland JM; Tawil R
Curr Opin Neurol; 2011 Oct; 24(5):423-8. PubMed ID: 21734574
[TBL] [Abstract][Full Text] [Related]
10. A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy.
Feng Q; Snider L; Jagannathan S; Tawil R; van der Maarel SM; Tapscott SJ; Bradley RK
Elife; 2015 Jan; 4():. PubMed ID: 25564732
[TBL] [Abstract][Full Text] [Related]
11. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.
Campbell AE; Belleville AE; Resnick R; Shadle SC; Tapscott SJ
Hum Mol Genet; 2018 Aug; 27(R2):R153-R162. PubMed ID: 29718206
[TBL] [Abstract][Full Text] [Related]
12. NuRD and CAF-1-mediated silencing of the D4Z4 array is modulated by DUX4-induced MBD3L proteins.
Campbell AE; Shadle SC; Jagannathan S; Lim JW; Resnick R; Tawil R; van der Maarel SM; Tapscott SJ
Elife; 2018 Mar; 7():. PubMed ID: 29533181
[TBL] [Abstract][Full Text] [Related]
13. Crystal Structure of the Double Homeodomain of DUX4 in Complex with DNA.
Lee JK; Bosnakovski D; Toso EA; Dinh T; Banerjee S; Bohl TE; Shi K; Orellana K; Kyba M; Aihara H
Cell Rep; 2018 Dec; 25(11):2955-2962.e3. PubMed ID: 30540931
[TBL] [Abstract][Full Text] [Related]
14. BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells.
Campbell AE; Oliva J; Yates MP; Zhong JW; Shadle SC; Snider L; Singh N; Tai S; Hiramuki Y; Tawil R; van der Maarel SM; Tapscott SJ; Sverdrup FM
Skelet Muscle; 2017 Sep; 7(1):16. PubMed ID: 28870238
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures.
Haynes P; Kernan K; Zhou SL; Miller DG
Skelet Muscle; 2017 Jun; 7(1):13. PubMed ID: 28637492
[TBL] [Abstract][Full Text] [Related]
16. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.
Haynes P; Bomsztyk K; Miller DG
Epigenetics Chromatin; 2018 Aug; 11(1):47. PubMed ID: 30122154
[TBL] [Abstract][Full Text] [Related]
17. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
[TBL] [Abstract][Full Text] [Related]
18. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones PL
Annu Rev Genomics Hum Genet; 2019 Aug; 20():265-291. PubMed ID: 31018108
[TBL] [Abstract][Full Text] [Related]
19. Loss of epigenetic silencing of the DUX4 transcription factor gene in facioscapulohumeral muscular dystrophy.
Hewitt JE
Hum Mol Genet; 2015 Oct; 24(R1):R17-23. PubMed ID: 26113644
[TBL] [Abstract][Full Text] [Related]
20. Antisense targeting of 3' end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach.
Marsollier AC; Ciszewski L; Mariot V; Popplewell L; Voit T; Dickson G; Dumonceaux J
Hum Mol Genet; 2016 Apr; 25(8):1468-78. PubMed ID: 26787513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
